EUVIMEDOpdag EUVIMED
Video/Audio

Laboratory-Engineered Glioblastoma Organoid Culture and Drug Screening

Changwen Wang, Nadja Stöffler, Hai-Kun Liu

Journal of Visualized Experiments · 2025-01-10 · (215)

DOI: 10.3791/67593 ↗

At a glance

Video/Audio in Journal of Visualized Experiments, published online on 2025-01-10. Written by Changwen Wang and 2 co-authors. Institution: Division of Molecular Neurogenetics, German Cancer Research Center (DKFZ); Department of Thyroid Surgery, The First Affiliated Hospital, School of Me…. Major MEDLINE topics: Glioblastoma, Organoids, Brain Neoplasms, Antineoplastic Agents. Cited 2 times so far (Crossref); 23 references.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Glioblastoma (GBM) is described as a group of highly malignant primary brain tumors and stands as one of the most lethal malignancies. The genetic and cellular characteristics of GBM have been a focal point of ongoing research, revealing that it is a group of heterogeneous diseases with variations in RNA expression, DNA methylation, or cellular composition. Despite the wealth of molecular data available, the lack of transferable pre-clinic models has limited the application of this information to disease classification rather than treatment stratification. Transferring the patients' genetic information into clinical benefits and bridging the gap between detailed descriptions of GBM, genotype-phenotype associations, and treatment advancements remain significant challenges. In this context, we present an advanced human GBM organoid model, the Laboratory Engineered Glioblastoma Organoid (LEGO), and illustrate its use in studying the genotype-phenotype dependencies and screening potential drugs for GBM. Utilizing this model, we have identified lipid metabolism dysregulation as a critical milestone in GBM progression and discovered that the microsomal triglyceride transfer protein inhibitor Lomitapide shows promise as a potential treatment for GBM.

Subjects

MeSH terms (MEDLINE)

GlioblastomaOrganoidsBrain NeoplasmsAntineoplastic AgentsHumansDrug Screening Assays, Antitumor

Substances

Antineoplastic Agents

Authors and institutions

  • Division of Molecular Neurogenetics, German Cancer Research Center (DKFZ); Department of Thyroid Surgery, The First Affiliated Hospital, School of Medicine, Zhejiang University.
  • Division of Molecular Neurogenetics, German Cancer Research Center (DKFZ).
  • Division of Molecular Neurogenetics, German Cancer Research Center (DKFZ); L.Haikun@dkfz-heidelberg.de.

Cite

APA

Wang, C., Stöffler, N., & Liu, H. K. (2025). Laboratory-Engineered Glioblastoma Organoid Culture and Drug Screening. Journal of Visualized Experiments. https://doi.org/10.3791/67593

Vancouver

Wang C, Stöffler N, Liu HK. Laboratory-Engineered Glioblastoma Organoid Culture and Drug Screening. Journal of Visualized Experiments. 2025. doi:10.3791/67593

BibTeX
@article{Wang2025,
  author = {Wang, Changwen and Stöffler, Nadja and Liu, Hai-Kun},
  title = {Laboratory-Engineered Glioblastoma Organoid Culture and Drug Screening},
  journal = {Journal of Visualized Experiments},
  year = {2025},
  number = {215},
  doi = {10.3791/67593}
}
Start for free →